Keyphrases
Platelet-derived Growth factor-BB (PDGF-BB)
100%
Graves' Ophthalmopathy
100%
Orbital Fibroblasts
37%
Orbital Tissue
12%
Tyrosine Kinase Inhibitor
12%
Growth Factor Signaling
12%
Factor System
12%
Pathophysiology
6%
Active Disease
6%
Dasatinib
6%
Platelet-derived Growth Factor Receptor (PDGFR)
6%
Adipocyte
6%
Orbital Fibroblast Activation
6%
Hyaluronan Production
6%
Hyaluronan
6%
Cytokine Production
6%
Thyroid Hormone Receptor
6%
Hormone Receptor Expression
6%
High Potency
6%
Platelet-derived Growth factor-AA
6%
Tissue Inflammation
6%
Inactive Disease
6%
Graves' Disease
6%
Nilotinib
6%
Therapeutic Rationale
6%
Ultra-low Dose
6%
Imatinib Mesylate
6%
Chemokine Production
6%
Main Determinants
6%
Tissue Expansion
6%
Therapeutic Approaches
6%
Autoantibodies
6%
Abnormal Proliferation
6%
Pharmacology, Toxicology and Pharmaceutical Science
Endocrine Ophthalmopathy
100%
Platelet Derived Growth Factor
100%
Platelet Derived Growth Factor BB
27%
Cytokine
18%
Hyaluronic Acid
18%
Platelet Derived Growth Factor AB
18%
Protein Tyrosine Kinase Inhibitor
18%
Disease
9%
Inflammation
9%
Dasatinib
9%
Platelet Derived Growth Factor Receptor
9%
Chemokine
9%
Pathophysiology
9%
Side Effect
9%
Nilotinib
9%
Graves Disease
9%
Autoantibodies
9%
Thyrotropin Receptor
9%
Imatinib
9%
Platelet Derived Growth Factor AA
9%
Biochemistry, Genetics and Molecular Biology
Platelet-Derived Growth Factor
100%
Fibroblast
41%
Isoform
17%
Cytokine
11%
Restylane
11%
Hyaluronan
11%
Tyrosine Kinase Inhibitor
11%
Chemokine
5%
Platelet-Derived Growth Factor Receptor
5%
Adipocyte
5%
Dasatinib
5%
Thyrotropin Receptor
5%
Low Drug Dose
5%
Nilotinib
5%
Autoantibodies
5%
Imatinib
5%
Mesylate
5%